Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UCHL1 | P09936 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | HTRA1 | Q92743 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.33 |
| ▸ | BCL2 | P10415 | 1/20 | 0.32 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | PPM1D | O15297 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2809688 | 1.00 | UCHL1 (0.39) | UCHL1HSD17B10NR1H2CYP1A2POLB | |
| SCHEMBL3832206 | 1.00 | UCHL1 (0.39) | UCHL1HSD17B10NR1H2CYP1A2POLB | |
| SCHEMBL2708045 | 1.00 | UCHL1 (0.39) | UCHL1HSD17B10NR1H2CYP1A2POLB | |
| SCHEMBL29203075 | 1.00 | UCHL1 (0.39) | UCHL1HSD17B10NR1H2CYP1A2POLB | |
| SCHEMBL18577100 | 1.00 | UCHL1 (0.39) | UCHL1HSD17B10NR1H2CYP1A2POLB | |
| SCHEMBL3832181 | 1.00 | UCHL1 (0.39) | UCHL1HSD17B10NR1H2CYP1A2POLB | |
| SCHEMBL9020470 | 0.90 | UCHL1 (0.34) | UCHL1HSD17B10NR1H2CYP1A2POLB | |
| SCHEMBL4300617 | 0.89 | UCHL1 (0.37) | UCHL1HSD17B10NR1H2CYP1A2POLB | |
| SCHEMBL4300613 | 0.89 | UCHL1 (0.37) | UCHL1HSD17B10NR1H2CYP1A2POLB | |
| SCHEMBL29548437 | 0.89 | UCHL1 (0.37) | UCHL1HSD17B10NR1H2CYP1A2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4583867-A2 | SODIUM CHANNEL BLOCKING COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE | Latigo Biotherapeutics, Inc. (US) | 2025-07-16 | — | — | EP | disclosed |
| US-12358886-B2 | Heterocyclic compounds for use in the treatment of cancer | ARTIOS PHARMA LIMITED (GB) | 2025-07-15 | — | — | US | disclosed |
| WO-2025122865-A1 | BIFUNCTIONAL ABL1-BINDING COMPOUNDS AND USES THEREOF | PHOTYS THERAPEUTICS, INC. (US) | 2025-06-12 | — | — | WO | disclosed |
| CN-119894509-A | Sodium channel blocking compounds, derivatives thereof, and methods of use thereof | 拉堤果生物医疗股份有限公司 | 2025-04-25 | — | — | CN | disclosed |
| CN-114667167-B | Heterocyclic compounds for the treatment of cancer | 阿提奥斯医药有限公司 | 2024-12-20 | — | — | CN | disclosed |
| EP-4405352-A1 | NEW COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION | F. Hoffmann-La Roche AG (CH) | 2024-07-31 | — | — | EP | disclosed |
| CN-117980303-A | Novel compounds and their use in the treatment of bacterial infections | 豪夫迈·罗氏有限公司 | 2024-05-03 | — | — | CN | disclosed |
| WO-2024054622-A2 | SODIUM CHANNEL BLOCKING COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE | LATIGO BIOTHERAPEUTICS, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| US-20230416199-A1 | INHIBITORS OF AMINO ACID TRANSPORT | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-12-28 | — | — | US | disclosed |
| EP-4010080-B1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LTD (GB) | 2023-09-27 | — | — | EP | disclosed |
| US-20070249637-A1 | Inhibitors Of Hepatitis C Virus Protease, And Compositions And Treatments Using The Same | COLLINS MICHAEL R | 2007-10-25 | — | — | US | disclosed |
| US-20070249637-A1 | Inhibitors Of Hepatitis C Virus Protease, And Compositions And Treatments Using The Same | COLLINS MICHAEL R | 2007-10-25 | — | — | US | disclosed |
| US-20060173056-A1 | Proline derivatives and use thereof as drugs | KITAJIMA HIROSHI | 2006-08-03 | — | — | US | disclosed |
| US-7074794-B2 | Proline derivatives and the use thereof as drugs | MITSUBISHI PHARMA CORPORATION (JP) | 2006-07-11 | — | — | US | disclosed |
| US-7060722-B2 | Proline derivatives and use thereof as drugs | MITSUBISHI PHARMA CORPORATION (JP) | 2006-06-13 | — | — | US | disclosed |
| US-20050261339-A1 | Pyrazole compound and medicinal composition containing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-11-24 | — | — | US | disclosed |
| US-20050245538-A1 | Proline derivatives and use thereof as drugs | KITAJIMA HIROSHI | 2005-11-03 | — | — | US | disclosed |
| EP-1510516-A1 | PYRAZOLE COMPOUND AND MEDICINAL COMPOSITION CONTAINING THE SAME | Eisai Co., Ltd. (JP) | 2005-03-02 | — | — | EP | disclosed |
| US-20040106655-A1 | Proline derivatives and the use thereof as drugs | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2004-06-03 | — | — | US | disclosed |
| EP-1308439-A1 | PROLINE DERIVATIVES AND USE THEREOF AS DRUGS | WELFIDE CORPORATION (JP) | 2003-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060173056-A1 | Proline derivatives and use thereof as drugs | DPP4, DPP3, DPP7 | UCHL1 1219/4885HSD17B10 1419/4885NR1H2 3309/4885 |
| US-20050245538-A1 | Proline derivatives and use thereof as drugs | DPP4, DPP3, DPP7 | UCHL1 1219/4885HSD17B10 1419/4885NR1H2 3309/4885 |
| US-20050261339-A1 | Pyrazole compound and medicinal composition containing the same | CNKSR1, NR3C2, CSNK2B | UCHL1 4487/4885HSD17B10 2288/4885NR1H2 115/4885 |
| US-20040106655-A1 | Proline derivatives and the use thereof as drugs | DPP4, DPP3, DPP7 | UCHL1 1337/4885HSD17B10 1217/4885NR1H2 3684/4885 |
| US-20230416199-A1 | INHIBITORS OF AMINO ACID TRANSPORT | SLC1A5, SLC7A1, SLC7A5 | UCHL1 3033/4885HSD17B10 1332/4885NR1H2 2000/4885 |
| US-20070249637-A1 | Inhibitors Of Hepatitis C Virus Protease, And Compositions And Treatments Using The Same | SERPINB1, CTSC, CTSV | UCHL1 330/4885HSD17B10 292/4885NR1H2 548/4885 |
| US-12358886-B2 | Heterocyclic compounds for use in the treatment of cancer | SDHA, DPYD, TP53 | UCHL1 3953/4885HSD17B10 1094/4885NR1H2 1131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.